Table 1 General characteristics of the HIV population: distribution according to the presence atheromatous plaque
Characteristics | Subjects without atherosclerotic plaque N = 69 (37.70%) Mean; SD N (%) | Subjects with atherosclerotic plaque N = 114 (62.29%) Mean; SD N (%) | p value | |
|---|---|---|---|---|
Age (years) | 48.51; 7.96 | 53.86; 8.20 | < 0.001 | |
Sex | ||||
Female | 20 (35.1%) | 37 (64.9%) | 0.623 | |
Male | 49 (38.9%) | 77 (61.1%) | ||
Hypertension | ||||
Yes | 21 (31.8%) | 45 (68.2%) | 0.217 | |
No | 48 (41%) | 69 (59%) | ||
Type 2 diabetes mellitus | ||||
Yes | 9 (29%) | 22 (71%) | 0.274 | |
No | 60 (39.5%) | 92 (60.5%) | ||
Dyslipidaemia | ||||
Yes | 22 (29.3%) | 53 (70.7%) | 0.052 | |
No | 47 (43.5%) | 61 (56.5%) | ||
Active smoking | ||||
Yes | 27 (27.3%) | 72 (72.7%) | 0.002 | |
No | 42 (50%) | 42 (50%) | ||
Family history of early CVD | ||||
Yes | 2 (18.2%) | 9 (81.8%) | 0.168 | |
No | 67 (39%) | 105 (61%) | ||
Total cholesterol (mg/dL) | 212.58; 46.87 | 218.81; 48.17 | 0.393 | |
LDL-C (mg/dL) | 145.50; 43.08 | 149.61; 46.30 | 0.551 | |
HDL-C (mg/dL) | 52.88; 16.13 | 54.91; 15.66 | 0.402 | |
Triglycerides (mg/dL) | 154.14; 121.31 | 145.24; 90.44 | 0.572 | |
Years of HIV infection** | 18.04; 7.98 | 22.11; 8.06 | 0.001 | |
Duration of viral suppression* (years) | 9.01; 4.76 | 10.03; 4.29 | 0.161 | |
CD4 cell nadir (cells/µL) | 231.94; 175.85 | 166.17; 141.4 | 0.010 | |
CD4/CD8 < 0.7 | ||||
Yes | 13 (22%) | 46 (78%) | 0.003 | |
No | 56 (45.2%) | 68 (54.8%) | ||
CD4/CD8 < 0.3 | ||||
Yes | 0 (0%) | 17 (100%) | 0.001 | |
No | 69 (41.6%) | 97 (58.4%) | ||
CD4/CD8 > 1.7 | ||||
Yes | 18 (100%) | 0 (0%) | < 0.001 | |
No | 51 (30.9%) | 114 (69.1%) | ||
Positive anti-HCV IgG | ||||
Yes | 17 (26.2%) | 48 (73.8%) | 0.017 | |
No | 52 (44.1%) | 66 (55.9%) | ||
IgG anti-CMV | ||||
Yes | 38 (36.5%) | 66 (63.4%) | 0.288 | |
No | 31 (39.2%) | 48 (60.7%) | ||
Treatment regimen with PI | ||||
Yes | 30 (29.4%) | 72 (70.6%) | 0.009 | |
No | 39 (48.1%) | 42 (51.9%) | ||
Treatment regimen with NRTI | ||||
Yes | 29 (43.3%) | 34 (30.6%) | 0.087 | |
No | 40 (33.3%) | 80 (66.6% | ||
Treatment regimen with NNRTI | ||||
Yes | 38 (56.71%) | 54 (48.60%) | 0.297 | |
No | 31(34.06%) | 60 (65.93%) | ||
Treatment regimen with INSTI | ||||
Yes | 27 (44.2%) | 34 (55.74%) | 0.442 | |
No | 42 (34.4%) | 80 (65.5%) | ||